These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23459393)

  • 1. Method for individualized evaluation of antiemetic effect induced by 5-HT3 receptor antagonist.
    Nakamura H; Yokoyama H; Yoshimoto K; Nakajima A; Okuyama K; Iwase O; Yamada Y
    Biol Pharm Bull; 2013; 36(5):780-7. PubMed ID: 23459393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.
    Nakamura H; Yokoyama H; Takayanagi R; Yoshimoto K; Nakajima A; Okuyama K; Iwase O; Yamada Y
    Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):39-44. PubMed ID: 24470169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].
    Yamada Y; Fujita M; Okuyama K; Takayanagi R; Ozeki T; Yokoyama H; Iga T
    Yakugaku Zasshi; 2007 Feb; 127(2):353-7. PubMed ID: 17268155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy.
    Endo J; Iihara H; Yamada M; Yanase K; Kamiya F; Ito F; Funaguchi N; Ohno Y; Minatoguchi S; Itoh Y
    Anticancer Res; 2012 Sep; 32(9):3939-47. PubMed ID: 22993341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of granisetron, a selective 5-HT3 receptor antagonist, on ouabain-induced emesis in ferrets.
    Endo T; Sugawara J; Nemoto M; Minami M; Blower PR
    Res Commun Mol Pathol Pharmacol; 1998 Dec; 102(3):227-39. PubMed ID: 10342910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy].
    Okuyama K; Yoshimoto K; Iwase O; Ozeki T; Yamada Y
    Yakugaku Zasshi; 2008 Apr; 128(4):649-55. PubMed ID: 18379183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granisetron: the second serotonin-receptor antagonist.
    Adams VR; Valley AW
    Ann Pharmacother; 1995 Dec; 29(12):1240-51. PubMed ID: 8672830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting.
    Rabasseda X
    Drugs Today (Barc); 2002 Feb; 38(2):75-89. PubMed ID: 12532186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Plosker GL; Benfield P
    Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High affinity binding of azasetron hydrochloride to 5-hydroxytryptamine3 receptors in the small intestine of rats.
    Katayama K; Asano K; Haga K; Fukuda T
    Jpn J Pharmacol; 1997 Apr; 73(4):357-60. PubMed ID: 9165374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?
    Blower P; Aapro M
    Br J Cancer; 2002 May; 86(10):1662-3; author reply 1664. PubMed ID: 12085221
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Addelman M; Erlichman C; Fine S; Warr D; Murray C
    J Clin Oncol; 1990 Feb; 8(2):337-41. PubMed ID: 2153767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers].
    Ishioka S; Sagae S; Saito T; Kiya T; Sugimura M; Akutagawa N; Umemura K; Ito E; Kudo R
    Gan To Kagaku Ryoho; 2000 Apr; 27(4):593-8. PubMed ID: 10791002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
    Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.